Prosecution Insights
Last updated: April 19, 2026
Application No. 18/547,251

POLYFLUORINATED CANNABINOID AND CANNABINOID-LIKE COMPOUNDS AND METHODS OF SYNTHESIS AND USE THEREOF

Non-Final OA §102
Filed
Aug 21, 2023
Examiner
SEITZ, ANTHONY JOSEPH
Art Unit
1629
Tech Center
1600 — Biotechnology & Organic Chemistry
Assignee
Burkhard Koenig
OA Round
1 (Non-Final)
68%
Grant Probability
Favorable
1-2
OA Rounds
3y 8m
To Grant
96%
With Interview

Examiner Intelligence

Grants 68% — above average
68%
Career Allow Rate
108 granted / 158 resolved
+8.4% vs TC avg
Strong +28% interview lift
Without
With
+27.5%
Interview Lift
resolved cases with interview
Typical timeline
3y 8m
Avg Prosecution
74 currently pending
Career history
232
Total Applications
across all art units

Statute-Specific Performance

§101
3.5%
-36.5% vs TC avg
§103
25.8%
-14.2% vs TC avg
§102
18.7%
-21.3% vs TC avg
§112
23.2%
-16.8% vs TC avg
Black line = Tech Center average estimate • Based on career data from 158 resolved cases

Office Action

§102
Notice of Pre-AIA or AIA Status The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . DETAILED ACTION Status of the Claims Claims 1-12 are pending and are examined on their merits. Priority Receipt is acknowledged of certified copies of papers required by 37 CFR 1.55. Claim Rejections - 35 USC § 102 In the event the determination of the status of the application as subject to AIA 35 U.S.C. 102 and 103 (or as subject to pre-AIA 35 U.S.C. 102 and 103) is incorrect, any correction of the statutory basis (i.e., changing from AIA to pre-AIA ) for the rejection will not be considered a new ground of rejection if the prior art relied upon, and the rationale supporting the rejection, would be the same under either status. The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action: A person shall be entitled to a patent unless – (a)(1) the claimed invention was patented, described in a printed publication, or in public use, on sale, or otherwise available to the public before the effective filing date of the claimed invention. Claim 1 is rejected under 35 U.S.C. 102(a)(1) as being anticipated by Kyulux (US 2020/0136060 A1 published on April 30th 2020). Claim 1 is directed towards a compound of Formula I: PNG media_image1.png 182 130 media_image1.png Greyscale . Kyulux teaches PNG media_image2.png 205 142 media_image2.png Greyscale (Kyulux, pg. 117), which is anticipatory of claim 1. Claim 7 is rejected under 35 U.S.C. 102(a)(1) as being anticipated by Burton (Burton et al., Preparation of p-substituted tetrafluoropyridyl derivatives via the tetrafluoropyridylcopper reagent, Journal of Fluorine Chemistry, Volume 135, 2012, Pages 144-154). Claim 7 is directed to a compound of Formula II: PNG media_image3.png 188 159 media_image3.png Greyscale . Burton teaches PNG media_image4.png 225 329 media_image4.png Greyscale (Burton, pg. 146, compound 10), anticipating claim 7. Allowable Subject Matter Claims 2-6 and 8-12 are free of the prior art. Claims 11-12 are allowed. Applicant has developed a series of polyfluorinated cannabinoid derivatives falling into the compound genera of Formulas I, II, and III: PNG media_image1.png 182 130 media_image1.png Greyscale (I) PNG media_image3.png 188 159 media_image3.png Greyscale (II) PNG media_image5.png 194 201 media_image5.png Greyscale .(III). Compounds of Formula I and II are found in the prior art in Kyulux (US 2020/0136060 A1 published on April 30th 2020) and Burton (Burton et al., Preparation of p-substituted tetrafluoropyridyl derivatives via the tetrafluoropyridylcopper reagent, Journal of Fluorine Chemistry, Volume 135, 2012, Pages 144-154), respectively. Formula III is free of the prior art. However, the compounds of Kyulux and Burton are relevant in the fields of organic light-emitting diodes and general organic synthesis, respectively, are not of particular relevance to applicant’s cannabinoid compounds, and only incidentally anticipate Formulas I and II. Thus, applicant’s further embodied compounds and further limitations to the R groups are nonobvious. Claims 2-6 and 8-10 are objected to as being dependent upon a rejected base claim, but would be allowable if rewritten in independent form including all of the limitations of the base claim and any intervening claims. Conclusion Any inquiry concerning this communication or earlier communications from the examiner should be directed to Anthony Seitz whose telephone number is (703)756-4657. The examiner can normally be reached 7:30 AM ET - 5:00 PM ET M-F. Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Jeffrey Lundgren can be reached at (571)272-5541. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. /A.J.S./Examiner, Art Unit 1629 /JEFFREY S LUNDGREN/Supervisory Patent Examiner, Art Unit 1629
Read full office action

Prosecution Timeline

Aug 21, 2023
Application Filed
Nov 21, 2025
Non-Final Rejection — §102 (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12599583
SMALL MOLECULE GRB2 STABILIZERS FOR RAS MAP KINASE INHIBITION
2y 5m to grant Granted Apr 14, 2026
Patent 12595263
PYRAZOLOPYRIMIDINE COMPOUND USED AS ATR KINASE INHIBITOR
2y 5m to grant Granted Apr 07, 2026
Patent 12590087
INHIBITING USP36
2y 5m to grant Granted Mar 31, 2026
Patent 12590080
NOVEL COMPOUNDS
2y 5m to grant Granted Mar 31, 2026
Patent 12583861
DERIVATIVES OF IMIDAZO[4,5-d]PYRIDAZINE, THEIR PREPARATION AND THEIR THERAPEUTIC APPLICATION
2y 5m to grant Granted Mar 24, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

AI Strategy Recommendation

Get an AI-powered prosecution strategy using examiner precedents, rejection analysis, and claim mapping.
Powered by AI — typically takes 5-10 seconds

Prosecution Projections

1-2
Expected OA Rounds
68%
Grant Probability
96%
With Interview (+27.5%)
3y 8m
Median Time to Grant
Low
PTA Risk
Based on 158 resolved cases by this examiner. Grant probability derived from career allow rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month